Inge Marie Svane

Studies on mRNA electroporation of immature and mature dendritic cells: effects on their immunogenic potential.

CD8 T-cell responses against cyclin B1 in breast cancer patients with tumors overexpressing p53.

High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer.

Identification of a cyclin B1-derived CTL epitope eliciting spontaneous responses in both cancer patients and healthy donors.

Characterization of ex vivo expanded tumor infiltrating lymphocytes from patients with malignant melanoma for clinical application.

Immunotherapy for metastatic colorectal cancer: present status and new options.

Tumor associated antigen specific T-cell populations identified in ex vivo expanded TIL cultures.

Generation of autologous tumor-specific T cells for adoptive transfer based on vaccination, in vitro restimulation and CD3/CD28 dynabead-induced T cell expansion.

Dissection of T-cell antigen specificity in human melanoma.

FDG PET scans as evaluation of clinical response to dendritic cell vaccination in patients with malignant melanoma.

Characterization of T-cell responses against IκBα in cancer patients.

Analysis of survivin-specific T cells in breast cancer patients using human DCs engineered with survivin mRNA.

Silencing of the glucocorticoid-induced leucine zipper improves the immunogenicity of clinical-grade dendritic cells.

The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4 T cells.

Broadening the repertoire of melanoma-associated T-cell epitopes.

Tryptophan 2,3-dioxygenase (TDO)-reactive T cells differ in their functional characteristics in health and cancer.

Indoleamine 2,3-dioxygenase vaccination.

Spontaneous presence of FOXO3-specific T cells in cancer patients.

Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies.

Tumor-infiltrating lymphocytes for the treatment of metastatic cancer.

Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.

Immune Monitoring Using mRNA-Transfected Dendritic Cells.

Transfection of Tumor-Infiltrating T Cells with mRNA Encoding CXCR2.

Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab.

Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study.

Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling.

PD-1 Polyfunctional T Cells Dominate the Periphery after Tumor-Infiltrating Lymphocyte Therapy for Cancer.

Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma.

Checkpoint inhibitors in breast cancer - Current status.

T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma-Implications for Adoptive Cell Therapy.

The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy.

Frequent adaptive immune responses against arginase-1.

Cancer immunotherapy in patients with brain metastases.

[Cancer immunotherapy].

Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical response.

The real-world impact of modern treatments on the survival of patients with metastatic melanoma.

Tumour-reactive T cell subsets in the microenvironment of ovarian cancer.

Collagen density regulates the activity of tumor-infiltrating T cells.

Correction: Tumour-reactive T cell subsets in the microenvironment of ovarian cancer.

MERTK Acts as a Costimulatory Receptor on Human CD8 T Cells.

Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma.

Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope.

Long-Term Exposure to Inflammation Induces Differential Cytokine Patterns and Apoptosis in Dendritic Cells.

CTLA-4 blockade boosts the expansion of tumor-reactive CD8 tumor-infiltrating lymphocytes in ovarian cancer.

Author Correction: Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma.

In vitro 4-1BB stimulation promotes expansion of CD8 tumor-infiltrating lymphocytes from various sarcoma subtypes.

T-Cell Gene Therapy in Cancer Immunotherapy: Why It Is No Longer Just CARs on The Road.

Escape from nonsense-mediated decay associates with anti-tumor immunogenicity.

Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma.

The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines.

The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study.

The capacity of CD4 Vγ9Vδ2 T cells to kill cancer cells correlates with co-expression of CD56.

Immune Cell Profiling of Peripheral Blood as Signature for Response During Checkpoint Inhibition Across Cancer Types.

Bone marrow toxicity and immune reconstitution in melanoma and non-melanoma solid cancer patients after non-myeloablative conditioning with chemotherapy and checkpoint inhibition.

Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma.

Lynch syndrome-associated epithelial ovarian cancer and its immunological profile.

Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types.